4bases, a Swiss-based leader in innovative genetic diagnostic solutions for Next Generation Sequencing (NGS), proudly announces the launch of InnoGraft — a non-invasive, cost-effective, and highly sensitive platform for longitudinal monitoring of solid organ transplant recipients.
InnoGraft detects donor-derived cell-free DNA (dd-cfDNA) in a recipient’s plasma, offering molecular evidence of graft injury days or even weeks before clinical symptoms or routine test abnormalities appear.
The platform leverages a proprietary panel of 94 highly polymorphic SNPs with high minor-allele frequency across ethnic groups, enabling donor–recipient differentiation without prior donor genotyping. It provides robust detection, even when donor DNA is present at very low levels.
InnoGraft is compatible with multiple NGS platforms and integrates a cloud-based, AI-driven analytics solution that quantifies dd-cfDNA percentage and evaluates rejection risk, delivering a digital report within 24 hours of sample receipt.
“InnoGraft marks a major milestone for 4bases — a culmination of cutting-edge research and our commitment to innovation. We see it as a paradigm shift in transplant care, and we welcome early adopters from the transplant community to join our Early Access Program” , said Fabio Grandi, COO and Co-founder.
InnoGraft is currently available as a Research Use Only (RUO) product and is protected by two patents.
About 4bases
4bases SA is a Swiss-based company specializing in the development, manufacturing, and commercialization of research and clinical-grade reagent kits for somatic and germline NGS analyses. The company is ISO 13485:2021 certified and continually innovates to meet the evolving needs of modern medicine.
Contact: info@4bases.ch
Website: www.4bases.ch
